What is MeMed?
MeMed is at the forefront of revolutionizing disease diagnostics and treatment by deciphering the intricate language of the immune system. The company leverages advanced host-response profiling and sophisticated machine-learning algorithms to develop a suite of tests designed to tackle challenging clinical dilemmas. This innovative approach aims to provide clear, actionable insights, thereby profoundly benefiting patients and advancing global healthcare.
How much funding has MeMed raised?
MeMed has raised a total of $93M across 1 funding round:
Private Equity
$93M
Private Equity (2022): $93M with participation from La Maison Partners, Social Capital, Horizons Ventures, and Shavit Capital
Key Investors in MeMed
La Maison Partners
La Maison Partners is an investment firm founded by entrepreneurs for entrepreneurs, focusing on venture capital, growth, and LBO strategies. They collaborate closely with ambitious management teams to build future champions.
Horizons Ventures
Horizons Ventures invests in deep science and technology aimed at advancing humanity, supporting innovative projects with the potential for transformative change.
Shavit Capital
Shavit Capital specializes in late-stage investments in Israeli and Israeli-related companies, focusing on businesses with proven technologies and strong management teams.
What's next for MeMed?
With a substantial enterprise-level funding history, MeMed is strategically positioned for accelerated growth and market penetration. The recent major strategic investment signals strong confidence from its backers, likely enabling the company to scale its operations, further develop its diagnostic portfolio, and expand its reach into new therapeutic areas. Future endeavors will likely focus on clinical validation, regulatory approvals, and broader commercialization of its groundbreaking technologies.
See full MeMed company page
